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Abstract 25 
The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited 26 
and beset by toxicity and emergent resistance. Furthermore, our understanding of drug 27 
mode-of-action and potential routes to resistance is limited. Forward genetic approaches 28 
have revolutionised our understanding of drug mode-of-action in the related kinetoplastid 29 
parasite, Trypanosoma brucei. Therefore, we screened our genome-scale T. brucei RNAi 30 
library against the current anti-leishmanial drugs, sodium stibogluconate (antimonial), 31 
paromomycin, miltefosine and amphotericin-B. Identification of T. brucei orthologues of the 32 
known Leishmania antimonial and miltefosine plasma membrane transporters effectively 33 
validated our approach, while a cohort of 42 novel drug efficacy determinants provides 34 
new insights and serves as a resource. Follow-up analyses revealed the antimonial 35 
selectivity of the aquaglyceroporin, TbAQP3. A lysosomal major facilitator superfamily 36 
transporter contributes to paromomycin/aminoglycoside efficacy. The vesicle-associated 37 
membrane protein, TbVAMP7B, and a flippase contribute to amphotericin-B and 38 
miltefosine action, and are potential cross-resistance determinants. Finally, multiple 39 
phospholipid-transporting flippases, including the T. brucei orthologue of the Leishmania 40 
miltefosine transporter, a putative β-subunit/CDC50 co-factor, and additional membrane-41 
associated hits, affect amphotericin-B efficacy, providing new insights into mechanisms of 42 
drug uptake and action. The findings from this orthology-based chemogenomic profiling 43 
approach substantially advance our understanding of anti-leishmanial drug action and 44 
potential resistance mechanisms, and should facilitate the development of improved 45 
therapies, as well as surveillance for drug-resistant parasites.  46 
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Introduction 47 
 The kinetoplastid parasites, Leishmania species, Trypanosoma brucei subspecies 48 
and T. cruzi are respectively endemic throughout much of the tropics and sub-tropics, sub-49 
Saharan Africa and Latin America. They are responsible for various forms of leishmaniasis 50 
(Leishmania spp.) (1), human African trypanosomiasis (HAT; T. b. gambiense and T. b. 51 
rhodesiense) and the livestock disease, nagana (T. b. brucei and related African 52 
trypanosomes) (2), and Chagas’ disease (T. cruzi) (3). Collectively, these parasites cause 53 
a huge burden of disease amongst predominantly poor populations in affected regions. 54 
Leishmaniasis is caused by a range of Leishmania species, leading to cutaneous and 55 
visceral forms of the disease, of which there are 0.7-1.3 and 0.2-0.4 million cases per year, 56 
respectively (4). While cutaneous leishmaniasis can be self-limiting, infections with L. 57 
braziliensis (and other members of the Viannia sub-genus) can develop into 58 
mucocutaneous leishmaniasis, a profoundly disfiguring form of the disease (4). Visceral 59 
leishmaniasis, also known as kala-azar, is typically fatal if untreated. 60 
There are four current anti-leishmanial drugs: sodium stibogluconate (SSG), 61 
paromomycin, miltefosine and amphotericin-B, which are unsatisfactory due to toxicity, 62 
emerging drug resistance, complex administration protocols and variable efficacy 63 
depending on the disease type or infecting Leishmania species (5). With the exception of 64 
miltefosine (in use against leishmaniasis since 2002), the current anti-leishmanial drugs 65 
have been in use for many decades. Until recently, efforts have focused on the 66 
development of more effective drug delivery regimens and combination therapies, with the 67 
aim of reducing dosages (and therefore side effects) and combating the emergence of 68 
resistance. The rise of antimonial resistant L. donovani on the Indian sub-continent now 69 
precludes the use of sodium stibogluconate (SSG) (6), while miltefosine resistant L. 70 
donovani has been confirmed in the clinic (7). Consequently, the World Health 71 
Organisation recommends various combination therapies, depending on the Leishmania 72 
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species and geographical region (8). However, it is relatively easy to generate Leishmania 73 
resistant to combination therapies in the laboratory (9, 10). More recently, new drugs have 74 
entered the clinical development pipeline. However, the most advanced of these, 75 
fexinidazole, which recently passed phase 2/3 clinical trials against HAT (11), and has 76 
anti-leishmanial activity in vitro (12), lacks efficacy in vivo (13). 77 
 Given the ease with which Leishmania parasites become resistant to the available 78 
drugs, it is critically important to understand how this resistance might develop. 79 
Identification of the genetic changes underlying drug resistance will enable the 80 
development of molecular diagnostics to inform treatment choice (14). Leishmania 81 
genome and transcriptome analyses have identified large numbers of candidate genes 82 
(15, 16) but relatively few have been directly linked to drug-action. While some drugs can 83 
freely move across membranes, many are taken up via specific surface receptors and 84 
transporters. For example, miltefosine uptake is dependent on a Leishmania amino 85 
phospholipid-transporting (P4)-type ATPase (or flippase) and its β-subunit/CDC50 co-86 
factor, Ros3 (17, 18), while the Sb(III) form of SSG is taken up via an aquaglyceroporin, 87 
AQP1 (19). There is also evidence that the ABC transporter, MRPA, influences SSG 88 
uptake and sequestration (20), and several other proteins have been implicated in SSG 89 
efficacy (reviewed in (14)). In addition, the generation of drug resistant Leishmania in the 90 
laboratory and various ‘omics analyses have provided insights into anti-leishmanial drug 91 
action and resistance mechanisms. Proteomic analyses of paromomycin resistant L. 92 
donovani revealed a complex picture, with a range of proteins upregulated, including 93 
several involved in translation regulation, vesicular trafficking and glycolysis (21). A similar 94 
analysis of amphotericin-B resistant L. infantum highlighted the differential expression of 95 
metabolic enzymes and the upregulation of proteins involved in protection against reactive 96 
oxygen species (22). Metabolomic analyses suggested that oxidative defence also 97 
contributes to SSG/amphotericin-B and SSG/paromomycin resistance in L. donovani (23). 98 
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The studies described above highlight the phenotypic consequences of changes in 99 
drug sensitivity, but not necessarily the genetic changes responsible. Forward genetic 100 
approaches can identify genes that contribute to drug action and resistance. For example, 101 
genome-scale RNAi library screening, coupled with RNA interference target sequencing 102 
(RIT-seq), has revolutionised our understanding of anti-HAT drug action and resistance 103 
(24, 25). In addition, the Cos-seq approach has enabled gain-of-function screening in 104 
Leishmania (26), leading to target validation for N-myristoyltransferase (27) and the 105 
identification of a panel of putative antimony and miltefosine resistance genes (28). While 106 
undoubtedly a powerful technique, Cos-seq is unable to identify drug uptake or activation 107 
mechanisms, which can be characterised by loss-of-function approaches, such as RIT-108 
seq. However, due to the absence of the RNAi machinery in most Leishmania species 109 
(with the notable exception of L. braziliensis (29)), this loss-of-function approach is not 110 
possible in these parasites. Although T. brucei and Leishmania have distinct life cycles, 111 
they are phylogenetically related kinetoplastid parasites that exhibit a high degree of 112 
biochemical and genetic similarity (30). Indeed, the majority of orthologous genes are 113 
syntenic, indicating little change in gene-order since divergence from a common ancestor. 114 
Perhaps not surprisingly then, several ‘dual-purpose’ drugs display activity against both 115 
parasites, including pentamidine (5), fexinidazole (11, 12) and the proteasome inhibitor, 116 
GNF6702 (31). T. brucei is also susceptible to in vitro killing by the four current anti-117 
leishmanial drugs. Therefore, we hypothesised that T. brucei RNAi library selection in the 118 
anti-leishmanial drugs would enable identification of candidate drug efficacy determinants 119 
with orthologues in Leishmania. 120 
Here, we describe RIT-seq library screening using each of the current anti-121 
leishmanial drugs. We identified 44 high confidence putative drug efficacy determinants, 122 
including the T. brucei orthologues of the Leishmania SSG and miltefosine transporters. 123 
Among many previously unknown drug efficacy determinants, we found that the vesicle-124 
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associated membrane protein, TbVAMP7B, contributes to miltefosine and amphotericin-B 125 
efficacy, and highlight a role for a cohort of amino phospholipid-transporting P4-ATPases 126 
(or ‘flippases’) in driving amphotericin-B efficacy. This collection of validated and putative 127 
anti-leishmanial drug efficacy determinants provides new insight into mode-of-action and 128 
potential resistance mechanisms, and represents an important resource to guide future 129 
study.  130 
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Results 131 
Orthology-based chemogenomic profiles for anti-leishmanial drugs 132 
The four current anti-leishmanial drugs, sodium stibogluconate (SSG), 133 
paromomycin, miltefosine and amphotericin-B, have in vitro EC50 values against T. brucei 134 
of 1.8 µg.ml-1, 17 µM, 30 µM and 260 nM, respectively (Fig. 1A). The equivalent values 135 
versus intracellular L. donovani amastigotes in mouse peritoneal macrophages are 136 
approximately an order of magnitude higher (SSG, paromomycin) or lower (miltefosine, 137 
amphotericin-B) (32). To identify factors whose loss renders T. brucei less sensitive to 138 
each anti-leishmanial drug, a bloodstream-form (BSF) T. brucei RNAi library was induced 139 
for 24 hours then each drug added at 1-3X EC50; selection and induction were maintained 140 
thereafter (Fig. 1B). After selection for approximately 10 days, populations with reduced 141 
drug sensitivity emerged and grew consistently under continued selection (Fig. 1C). 142 
Following robust growth for at least two days, genomic DNA was isolated from the 143 
drug-selected populations and subjected to RNAi construct-specific PCR, generating 144 
distinct banding patterns for each (Fig. 1C). We sequenced the amplified RNAi target 145 
fragment populations from the selected RNAi libraries on an Illumina HiSeq platform 146 
(Table S1). For each selected RNAi library, we mapped more than three million individual 147 
sequence reads, representing anti-leishmanial enriched RNAi target fragments, to the 148 
TREU927 T. brucei reference genome (33) using our established RIT-seq methodology 149 
(34) (Fig. 1B). The presence of the RNAi construct-specific barcode identified ‘high 150 
confidence’ hits, i.e. those represented by more than 99 barcoded 151 
reads/kilobase/predicted transcript (open reading frames plus predicted untranslated 152 
regions, as annotated in the TREU927 reference genome available at www.tritrypdb.org), 153 
and recovery of at least two independent RNAi target fragments (Fig. 2; Fig. S1; Table 154 
S1). 155 
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Importantly, we identified T. brucei orthologues of two known Leishmania 156 
determinants of anti-leishmanial drug efficacy. RNAi target fragments that mapped to the 157 
TbAQP2-3 locus (Tb927.10.14160-70), which encodes two aquaglyceroporins, dominated 158 
the SSG-selected RNAi library; L. donovani AQP1 (LdBPK_310030.1) is a key mediator of 159 
SSG uptake (19). Another significant hit identified following miltefosine selection was a 160 
putative flippase (Tb927.11.3350); the corresponding coding sequence is syntenic with the 161 
L. donovani miltefosine transporter (LdBPK_131590.1) (17). The identification of T. brucei 162 
orthologues of these known anti-leishmanial efficacy determinants highlights the power of 163 
this chemogenomic profiling approach in the identification of mechanisms of action and 164 
resistance that are also relevant to Leishmania parasites. In addition to these hits, our RIT-165 
seq analyses yielded a further 42 high confidence hits (Fig. 2; Fig. S1; Table S1). 166 
 167 
TbAQP3, an orthologue of Leishmania AQP1, is linked to antimonial action. 168 
Aquaglyceroporin defects in T. brucei and in Leishmania have been linked to 169 
arsenical and antimonial resistance (see above), but specific relationships among drugs 170 
and AQPs have not been fully elucidated.  For example, TbAQP2 is responsible for 171 
pentamidine and melarsoprol uptake (35), possibly via receptor-mediated endocytosis in 172 
the former case (36), and mutations that disrupt TbAQP2 are responsible for melarsoprol 173 
resistance in patients (37). L. donovani AQP1 has also been linked to antimonial 174 
resistance in patients (38). Notably, TbAQP3 and Leishmania AQP1 have the same set of 175 
selectivity filter residues (NPA/NPA/WGYR), while TbAQP2 has a divergent set 176 
(NSA/NPS/IVLL) (39). Therefore, we investigated the specificity of the interaction between 177 
SSG and TbAQP2/TbAQP3, the major hits in the SSG screen. 178 
 Sequence mapping of the RNAi target fragments following SSG selection revealed 179 
that approximately 71% and 29% of mapped reads containing the RNAi construct-specific 180 
barcode corresponded to TbAQP2 (Tb927.10.14170) and TbAQP3 (Tb927.10.14160), 181 
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respectively (Fig. 3A); only 0.08% of reads mapped elsewhere in the genome. These data 182 
are consistent with the idea that both aquaglyceroporins contribute to SSG action. 183 
However, theTbAQP2 and TbAQP3 coding sequences are 82.3% identical, thus while an 184 
RNAi fragment may unambiguously map to TbAQP2, it may be sufficiently similar to 185 
TbAQP3 to elicit its depletion. Therefore, we tested the relative contribution of the encoded 186 
aquaglyceroporins to SSG action against T. brucei using aqp2-3 null and re-expression 187 
cell lines (35). 188 
Deletion of the TbAQP2-3 locus led to a 6.7-fold increase in SSG EC50 (Fig. 3B), 189 
consistent with the output from the screen. Inducible expression of GFPTbAQP2 in the null 190 
cell line had little effect on T. brucei SSG sensitivity (Fig. 3C, left-hand panel); however, 191 
GFPTbAQP3 expression reduced the SSG EC50 5.5-fold (Fig. 3C, right-hand panel). In 192 
contrast, and as shown previously (35), GFPAQP2 expression complemented the 193 
pentamidine resistance of aqp2-3 null T. brucei (Fig. 3D, left-hand panel), while GFPAQP3 194 
expression had no effect on pentamidine sensitivity (Fig. 3C, right-hand panel). Therefore, 195 
SSG sensitivity and resistance is specifically determined by TbAQP3 expression. This 196 
indicates that the NPA/NPA/WGYR selectivity filter, present in both TbAQP3 (39) and 197 
Leishmania AQP1, may be selective for antimonial uptake. 198 
 199 
T. brucei lysosomal MFST influences aminoglycoside action. 200 
Selection of the BSF T. brucei RNAi library with the anti-leishmanial 201 
aminoglycoside, paromomycin, identified 50 hits, of which 28 fulfilled our high stringency 202 
criteria (Table S1). Twenty-one of the high confidence hits were functionally annotated, 203 
and included several associated with transport and nucleic acid processing. The top three 204 
hits with functional annotations were Tb927.9.6360-80 (major facilitator superfamily 205 
transporters, MFST), Tb927.11.6680 (amino acid transporter, AAT15) and 206 
Tb927.11.14190 (Tudor domain-containing Staphylococcal nuclease, TSN) (40), targeted 207 
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by approximately 84%, 1.7% and 0.9% of the mapped reads, respectively (Fig. 4A, Fig. S2 208 
and Table S1). However, while parasites able to deplete AAT15 and TSN persisted in the 209 
population over the 12 days of selection in paromomycin, we were unable to detect a 210 
significant advantage versus wild type T. brucei during the course of a standard 72-hour 211 
EC50 assay (Fig. S1). Therefore, we focussed our attention on the MFST genes. 212 
The genes at the Tb927.9.6360-80 locus share at least 92% sequence identity and 213 
encode for three putative MFSTs, a ubiquitous family of proteins responsible for 214 
membrane transit of a wide range of solutes including drugs (41). Comparison with the 215 
sequences annotated ‘MFS’ or ‘major facilitator superfamily transporter’ in the L. major 216 
reference genome confirmed that the syntenic coding sequence, LmjF.15.0870, is most 217 
closely related to Tb927.9.6360-80 (Fig. 4B; Fig. S3). The Leishmania and T. brucei 218 
proteins share a similar trans-membrane domain organisation and the cytoplasmic loop 219 
between TM6 and TM7, which is characteristic of MFST proteins (Fig. 4C) (42). 220 
We previously identified the Tb927.9.6360-80 locus as a key contributor to suramin 221 
efficacy against T. brucei, with RNAi depletion of the three transcripts leading to a ten-fold 222 
reduction in parasite sensitivity to suramin; localisation studies also indicated that at least 223 
one of these transporters is lysosomal (24). Deletion of the whole locus (Fig. 4D) revealed 224 
that the three encoded proteins are collectively dispensable in cultured BSF T. brucei (Fig. 225 
4E), and enabled us to confirm that not only do these proteins influence suramin efficacy 226 
(Fig. 4F), but also that of paromomycin (Fig. 4G) and the related aminoglycoside, 227 
neomycin (Fig. 4H). While loss of these MFST proteins dramatically reduces suramin 228 
efficacy, the effect on paromomycin and neomycin sensitivity is less pronounced (1.5 and 229 
2.8-fold EC50 increase, respectively), though significant. Our mutant BSF T. brucei also 230 
exhibited better tolerance than wild type parasites to the aminoglycosides at 231 
concentrations equivalent to greater than EC99 during the first 24 hours of exposure (Fig. 232 
S4). 233 
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 234 
TbVAMP7B, a cross-efficacy determinant for amphotericin-B and miltefosine. 235 
To identify anti-leishmanial cross-efficacy determinants, we next used pairwise 236 
comparisons of RNAi library screen outputs (Fig. 5). We first identified a small cohort of 237 
hits represented by at least two RNAi target fragments and >99 reads/kilobase/transcript in 238 
more than one screen. This group included the AQP2-3 locus, represented by at least 100 239 
reads in all four screens. We did not explore this locus further since the read-count was at 240 
least three orders of magnitude lower in each screen relative to the SSG screen, and 241 
leishmanial AQPs have not been implicated in resistance to the other drugs (see above). 242 
Two other loci fulfilled our stringency criteria, and both were enriched following 243 
amphotericin-B and miltefosine selection: Tb927.5.3550-70 and Tb927.11.3350 (Table 244 
S1); further analysis of the former hit is considered in this section, while the contribution of 245 
Tb927.11.3350 to drug action is addressed subsequently. 246 
RIT-seq analysis revealed that 2.2% and 97% of mapped reads identified 247 
Tb927.5.3550-70 in the amphotericin-B and miltefosine screens, respectively (Fig. 6A). 248 
This locus encodes for a thioredoxin-like protein (Tb927.5.3550), a vesicle-associated 249 
membrane protein, TbVAMP7B (Tb927.5.3560) (43), and a hypothetical protein 250 
(Tb927.5.3570). Analysis of the RNAi target fragments mapping to Tb927.5.3550-70 251 
revealed that few uniquely targeted the TbVAMP7B coding sequence (Fig. 6A). Instead, 252 
the RNAi target fragments that mapped to the flanking genes overlapped either the 253 
TbVAMP7B coding sequence (3550 RNAi target fragments) or 3’-untranslated region 254 
(3570 RNAi target fragments). This pattern is consistent with poor tolerance of TbVAMP7B 255 
depletion. Our previous high-throughput phenotypic analysis indicated that TbVAMP7B 256 
RNAi knockdown is associated with a significant loss of fitness, while depletion of the 257 
flanking transcripts had a less dramatic effect (Table S1) (44). Taken together, these data 258 
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suggested that TbVAMP7B is an amphotericin-B/miltefosine cross-efficacy determinant, 259 
while the identification of the flanking genes was due to bystander effects. 260 
To test this hypothesis, we generated stem-loop RNAi BSF T. brucei cell lines 261 
targeting TbVAMP7B and Tb927.5.3570. As predicted, depletion of Tb927.5.3570 had no 262 
effect on growth or sensitivity to amphotericin-B or miltefosine (Fig. S5). In contrast, 263 
knockdown of TbVAMP7B following induction in tetracycline at 2 ng or 1 μg.ml-1 resulted in 264 
a significant growth defect (Fig. 6B). To assess the contribution of TbVAMP7B to drug 265 
efficacy, we induced RNAi in 2 ng.ml-1 tetracycline for 24 hours and assessed drug 266 
sensitivity over a further 30 hours under inducing conditions. Incubation in low 267 
concentration tetracycline and a shorter EC50 analysis (as opposed to the standard 72-268 
hour protocol) ensured that the growth defect due to TbVAMP7B RNAi knockdown was 269 
minimised, while still allowing us to test the protein’s contribution to drug action.  270 
 Unexpectedly, RNAi knockdown of TbVAMP7B reduced the amphotericin-B EC50, 271 
by 24% (Fig. 6C).  However, TbVAMP7B depletion also resulted in a significant decrease 272 
in the Hill coefficient. Consequently, while the EC50 decreased upon TbVAMP7B depletion, 273 
the EC90 and EC99 increased 1.45-fold and 3-fold, respectively (Fig. 6D); the EC25 274 
decreased by 44%, consistent with the effect on the EC50 and the change in the Hill 275 
coefficient. Therefore, small changes in TbVAMP7B expression can lead to significant loss 276 
of sensitivity to high concentration amphotericin-B, while enhancing sensitivity to the drug 277 
at low concentration. This relative resistance to high concentration amphotericin-B 278 
explains the enrichment of TbVAMP7B-targeting RNAi fragments following selection of the 279 
RNAi library in 1.5x EC50. In contrast, miltefosine at relatively low concentrations 280 
complemented the TbVAMP7B RNAi growth defect and further increased growth at lower 281 
concentrations (Fig. 6E, F). 282 
Our findings indicate specific interactions between TbVAMP7B and both 283 
amphotericin-B and miltefosine. VAMP7 proteins are involved in endosome and lysosome 284 
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membrane fusion (45) and it is notable in this respect that amphotericin-B disrupts 285 
membranes and miltefosine is a phospholipid drug. TbVAMP7B depletion does not 286 
significantly increase the EC50 for either drug but, nevertheless, these interactions may be 287 
important in a clinical setting where exposure will be variable in different tissues and at 288 
different times following dosing. 289 
 290 
Multiple hits link amphotericin-B action to phospholipid transport and metabolism. 291 
Our amphotericin-B screen yielded thirteen high-confidence hits, for which Gene-292 
Ontology term profiling revealed links to membranes and lipids (Table S2; Fig. S6). This is 293 
consistent with disruption of membranes by amphotericin-B.  Miltefosine uptake in 294 
Leishmania is dependent on a flippase (17, 18), which also contributes to the anti-295 
leishmanial action of amphotericin-B (46). RNAi fragments targeting the syntenic locus in 296 
T. brucei, Tb927.11.3350, were enriched following selection in amphotericin-B and 297 
miltefosine (Fig. 5; Fig. 7A). Depletion of Tb927.11.3350, while having no effect on 298 
parasite growth in culture (Fig. 7B), led to a reproducible increase in amphotericin-B and 299 
miltefosine EC50 (Fig. 7C, D). RNAi knockdown also significantly enhanced short-term 300 
survival in high concentration amphotericin-B and miltefosine (Fig. S6). Therefore, as in 301 
Leishmania, the T. brucei miltefosine transporter orthologue contributes to the action of 302 
miltefosine and amphotericin-B. 303 
In addition to Tb927.11.3350, the T. brucei genome contains three other putative 304 
flippases (Fig. 8A), as well as three putative β-subunits, including Tb927.11.13770, the 305 
syntenic orthologue of Leishmania Ros3 (18). Three of the four flippases (Tb927.4.1510, 306 
Tb927.11.3350 and Tb927.11.13000) have a similar domain organisation to the yeast 307 
flippases and possess the DEGT and DKTGT motifs characteristic of the actuator and 308 
phosphorylation domains (47). The fourth, Tb927.6.3550, lacks the flippase DEGT domain, 309 
although it clusters with the Leishmania flippase, LmjF.34.2630. However, it also lacks the 310 
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TGES domain characteristic of the related cation transporting P-type ATPases, such as 311 
yeast Pay2 (47), so its identity is unclear (Fig. 8A). 312 
In addition to the Leishmania miltefosine transporter orthologue, Tb927.11.3350, 313 
RNAi fragments targeting the flippases, Tb927.11.13000 and Tb927.6.3550, and the β-314 
subunit, Tb927.11.13200, were enriched following selection in amphotericin-B, with 315 
Tb927.11.13000 represented by 78% of mapped reads (Fig. 8B; Table S1). Targeted RNAi 316 
depletion of Tb927.11.13000 led to a mild growth defect (Fig. 8C) and a more than two-317 
fold EC50 increase, validating this protein as an amphotericin-B efficacy determinant in T. 318 
brucei (Fig. 8D). The impact of Tb927.11.13000 depletion was most pronounced during 319 
the initial 24 hours of drug exposure, enabling the parasite population to increase 320 
approximately 1.3-fold and four-fold over eight and 24 hours, respectively, in the presence 321 
of 0.7 µM (>EC99) amphotericin-B (Fig. S6). The uninduced population declined by more 322 
than 40% and 60% over the same periods. In addition, while exposure to 1.8 µM (>EC99.9) 323 
amphotericin-B led to an 80% decline in the induced population over 24 hours, cultures of 324 
uninduced cells were cleared within four hours exposure to this drug concentration (Fig. 325 
S6). Depletion of this putative phospholipid-transporting ATPase had no effect on 326 
miltefosine efficacy (Fig. 8E) confirming its specific contribution to amphotericin-B action. 327 
 Our results reveal that multiple T. brucei flippases drive the efficacy of 328 
amphotericin-B, all of which have syntenic orthologues in Leishmania (Fig. 8A). Therefore, 329 
in addition to the well-characterised miltefosine-transporting flippase, other Leishmania 330 
flippases may play significant, and potentially specific, roles in the anti-leishmanial action 331 
of amphotericin-B and miltefosine. 332 
 333 
Discussion 334 
In the current absence of an effective genome-scale loss-of-function screen in 335 
Leishmania, we speculated that selection of a T. brucei RNAi library would provide insights 336 
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into anti-leishmanial drug action, while also revealing novel T. brucei biology. By selecting 337 
our genome-scale BSF T. brucei RNAi library in the current anti-leishmanial drugs followed 338 
by RIT-seq analysis, we identified a panel of putative anti-leishmanial drug efficacy 339 
determinants (Table S1 and Fig. S1). SSG and miltefosine selection respectively identified 340 
TbAQP3, an orthologue of the known Sb(III) transporter, and Tb927.11.3350, the T. brucei 341 
orthologue of the Leishmania miltefosine transporter, confirming the power of this 342 
approach. In addition to these known drug transporters, we validated several novel drug 343 
efficacy determinants identified by our selective screens: Tb927.9.6360-80 (paromomycin), 344 
Tb927.5.3560 (miltefosine and amphotericin-B) and Tb927.11.13000 (amphotericin-B). 345 
Our results highlight the role of a lysosomal transporter in paromomycin efficacy, 346 
emphasise the importance of membrane composition in the action of amphotericin-B and 347 
miltefosine, provide insight into the substrate selectivity of the trypanosomatid 348 
aquaglyceroporins, and present several new candidate anti-leishmanial drug efficacy 349 
determinants (Fig. 9). 350 
SSG contains Sb(V), which is not reduced in Leishmania media, limiting its efficacy 351 
against the extracellular promastigote stage (48). However, once it enters the host 352 
macrophage, it is thought to be reduced to the toxic Sb(III) form, which can be taken up by 353 
intracellular Leishmania amastigotes via AQP1 (19, 49). In contrast, we speculate that 354 
Sb(V) is reduced to Sb(III) in T. brucei HMI9 media due to the presence of supplementary 355 
L-cysteine (50). Thus, in common with intracellular Leishmania amastigotes, cultured 356 
extracellular T. brucei treated with SSG are exposed to toxic Sb(III). T. brucei RNAi library 357 
selection in SSG and our subsequent validation experiments identified a single efficacy 358 
determinant, TbAQP3. Aquaglyceroporins are ubiquitous transporters of water, glycerol 359 
and other small solutes, whose specificity is defined by their selectivity filter residues. 360 
Leishmania AQP1 and the T. brucei proteins, TbAQP1 and TbAQP3, have the same 361 
selectivity filter, NPA/NPA/WGYR, while TbAQP2 possesses a divergent filter, 362 
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NSA/NPS/IVLL (39). TbAQP2 is a key drug transporter in T. brucei, mediating the uptake 363 
of pentamidine and melarsoprol, and its loss contributes to clinical drug resistance (35-37). 364 
In addition, TbAQP2 plays an important role in glycerol transport, as its loss increases 365 
parasite sensitivity to alternative oxidase inhibition, which leads to elevated intracellular 366 
glycerol levels (51). The in vivo roles of the other T. brucei aquaglyceroporins remain 367 
unknown, though all three are capable of arsenite and antimonite transport in yeast and 368 
Xenopus heterologous expression systems (52). In contrast, our data demonstrate that in 369 
T. brucei these transporters are selective for arsenic-containing melarsoprol (TbAQP2; 370 
(35)) and Sb(III) (TbAQP3). Intriguingly, RNAi library selection in SSG failed to identify 371 
TbAQP1 even though it contains the same selectivity filter as TbAQP3. This suggests 372 
important functional and regulatory differences between TbAQP1 and TbAQP3, which may 373 
influence their ability to contribute to Sb(III) uptake in bloodstream-form T. brucei. For 374 
example, TbAQP3 is localised to the plasma membrane in bloodstream-form T. brucei and 375 
TbAQP1 localises to the flagella membrane (35, 53). This differential localisation may 376 
influence their ability to mediate antimonial uptake. 377 
The aminoglycoside, paromomycin, is thought to inhibit protein synthesis in 378 
Leishmania and enters the cell via endocytosis (21, 54, 55). However, RNAi library 379 
selection did not identify a surface receptor suggesting that, at least in T. brucei, 380 
paromomycin entry is not dependent on a specific ligand-receptor interaction. Rather, the 381 
high endocytic flux associated with surface VSG internalisation (56) may drive drug 382 
uptake. In addition, our screen did not identify proteins with identifiable roles in 383 
translational regulation. This perhaps surprising observation may be due to the relative 384 
essentiality of such proteins, whose loss, while capable of affecting paromomycin action, 385 
may also cause substantial loss of fitness. Instead, RNAi fragments targeting 386 
Tb927.9.6360-80 dominated the paromomycin-selected RNAi library, with the remaining 387 
28 high confidence hits constituting only 9% of mapped reads. This locus encodes a set of 388 
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closely related MFST proteins, at least one of which localises to the lysosome, and has 389 
previously been associated with suramin efficacy (24). In contrast to paromomycin, several 390 
other endocytic pathway proteins, including three lysosomal proteins (p67, cathepsin-L 391 
and the MFST proteins), influence suramin efficacy (24). This led to the proposal that 392 
proteolytic processing in the lysosome releases suramin from bound proteins, enabling 393 
neutralisation in the acidic environment or association with an alternative endogenous 394 
carrier and escape to the cytoplasm via one or more of the lysosomal MFSTs (57). In 395 
contrast, the absence of hits targeting other endocytic components following paromomycin 396 
RNAi library selection suggests little reliance on the endocytic network per se. Therefore, 397 
the lysosomal MFST proteins may influence paromomycin efficacy indirectly. MFST 398 
proteins mediate the transit of a diverse range of molecules, including polyamines and 399 
amino acids (41), and changes in the intracellular flux of these molecules may affect 400 
translation efficiency, which in turn may influence paromomycin efficacy. Deletion of the 401 
Tb927.9.6360-80 locus from T. brucei yields only a two-fold increase in paromomycin 402 
EC50. However, the MFST protein encoded by the syntenic single copy gene in 403 
Leishmania (e.g. LmjF.15.0870) remains to be characterised and may make a more 404 
substantial contribution to paromomycin action against this parasite. 405 
Combination therapies are increasingly being used to treat leishmaniasis, enabling 406 
reduced dosing and treatment duration, resulting in fewer side effects (8). For example, a 407 
single dose of liposomal amphotericin-B in combination with a short course of oral 408 
miltefosine or intramuscular paromomycin is an effective treatment for visceral 409 
leishmaniasis (VL) in the Indian sub-continent (58). In East Africa, SSG-paromomycin 410 
combination therapy is effective against VL (59). However, L. donovani resistant to these 411 
and other anti-leishmanial drug combinations can be selected for in vitro (9, 10), and 412 
oxidative defence upregulation and changes in membrane fluidity have been associated 413 
with cross-resistance in laboratory-derived lines (23). Therefore, we carried out pairwise 414 
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comparisons of our RNAi library screen data to identify potential cross-efficacy 415 
determinants. Only two hits fulfilled our stringency criteria, both of which influence 416 
amphotericin-B and miltefosine action: TbVAMP7B, an endosomal SNARE protein 417 
responsible for endosomal-lysosomal fusion in other eukaryotes (45, 60), and 418 
Tb927.11.3350, the T. brucei orthologue of the Leishmania miltefosine transporter (17). 419 
However, while both of these proteins may influence membrane fluidity (see below), it 420 
seems unlikely that either contributes significantly to oxidative defence. Recent Cos-seq 421 
gain-of-function analyses in L. infantum identified several candidate proteins whose 422 
overexpression reduces sensitivity to multi-drug exposure (26); these also lack an obvious 423 
connection to oxidative defence. Therefore, rather than being dependent on the increase 424 
or decrease in expression of a single protein, changes in oxidative defence that lead to 425 
anti-leishmanial resistance are likely to be multi-factorial. Our findings also suggest that 426 
miltefosine/amphotericin-B combination therapy is the most vulnerable to loss-of-function 427 
mutation, while others may be less susceptible to the down-regulation of a single protein. 428 
This finding is particularly significant, given that recent trials have confirmed the efficacy of 429 
amphotericin-B/miltefosine combination therapy in treating VL (61, 62).  430 
In contrast to the other anti-leishmanial drug efficacy determinants described 431 
herein, TbVAMP7B depletion does not simply increase the drugs’ EC50. Instead, 432 
TbVAMP7B RNAi knockdown reduces amphotericin-B EC50 and has little effect on 433 
miltefosine EC50. The drop in amphotericin-B EC50 is due to a substantial decrease in the 434 
amphotericin-B Hill coefficient, which has the opposite effect on EC90 and EC99, increasing 435 
both and enabling TbVAMP7B-depleted parasites to persist at these drug concentrations. 436 
Our data shows that T. brucei has limited tolerance for TbVAMP7B depletion, presumably 437 
due to impairment of endosomal-lysosomal fusion (45). Intriguingly, exposure to low 438 
concentration miltefosine complements the growth defect seen following TbVAMP7B 439 
depletion, suggesting that miltefosine treatment is able to promote vesicle membrane 440 
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fusion in the endocytic system, a possible consequence of the enhanced membrane 441 
fluidity seen upon miltefosine exposure (63). TbVAMP7B has also recently been identified 442 
as a putative T. brucei apolipoprotein-L1 sensitivity determinant (64), and other workers 443 
have highlighted the importance of the intracellular transit of apoL1-carrying membrane to 444 
trypanolysis (65, 66). Our findings suggest that such transit also contributes to 445 
amphotericin-B and miltefosine action. The VAMP7 proteins are highly conserved between 446 
T. brucei and Leishmania (43), suggesting that Leishmania parasites will also be sensitive 447 
to VAMP7B loss (LmjF.08.0030). However, subtle changes in VAMP7B expression that 448 
can be tolerated may enable parasites to take advantage of variations in amphotericin-B 449 
and miltefosine tissue penetrance.  450 
 Miltefosine uptake in Leishmania is dependent on a phospholipid-transporting 451 
flippase (the miltefosine transporter, MT) and its β-subunit, Ros3 (17, 18); both in vitro 452 
selected lines and miltefosine resistant L. donovani clinical isolates harbour mutations in 453 
the MT (7, 67, 68). Consistent with this, T. brucei RNAi library selection in miltefosine led 454 
to enrichment for RNAi fragments mapping to the syntenic sequence in T. brucei 455 
(Tb927.11.3350). RNAi library selection in amphotericin-B also enriched for RNAi 456 
fragments mapping to this gene, consistent with recent findings in Leishmania (46), as well 457 
as two other flippases and a putative β-subunit (Tb927.11.13200). Interestingly, the β-458 
subunit targeted was not the syntenic orthologue of Ros3, previously shown to interact 459 
with the MT (18). Therefore, different flippase/β-subunit dependencies may have evolved 460 
following divergence of the Leishmania and T. brucei lineages. A further difference in the 461 
behaviour of these proteins between Leishmania and T. brucei lies in their localisation. 462 
The MT and Ros3 localise to the plasma membrane in Leishmania (18), whereas in 463 
procyclic form  T. brucei, the MT orthologue (Tb927.11.3350) and a second flippase 464 
(Tb927.11.13000) localise to an intracellular structure reminiscent of the endosomal 465 
system (www.TrypTag.org; (69)); their localisation in BSF T. brucei is unknown. Therefore, 466 
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while flippases influence drug action against Leishmania and T. brucei, they may mediate 467 
drug and/or phospholipid transit across different membranes in each parasite. 468 
Phospholipid transport by flippases maintains the membrane asymmetry necessary 469 
for membrane fusion, vesicle trafficking and sterol homeostasis (47). The identification of a 470 
single flippase following miltefosine selection is consistent with its role as a drug 471 
transporter (17). In contrast, amphotericin-B selection identified three flippases, suggesting 472 
an indirect role in drug action, possibly through changes in membrane composition and 473 
transit through the endosomal system (Fig. 9). Amphotericin-B acts by binding membrane 474 
ergosterol (70), leading to the formation of ion-permeable channels and downstream 475 
oxidative damage (71). Consistent with the importance of ergosterol to amphotericin-B 476 
action, resistant clinical isolates exhibit elevated membrane fluidity and reduced ergosterol 477 
content (72). Recent findings have highlighted the mutation of key sterol biosynthetic 478 
enzymes, such as CYP51, and reduced ergosterol production, as drivers of resistance in 479 
laboratory-derived amphotericin-B resistant L. mexicana (73, 74). In contrast, 480 
amphotericin-B selection of the BSF T. brucei RNAi library did not identify TbCYP51 481 
(Tb927. 11.6210) or any other recognisable component of the ergosterol biosynthetic 482 
pathway, suggesting that limiting ergosterol production in BSF T. brucei is unable to 483 
reduce amphotericin-B efficacy. However, our data indicate that changes in flippase 484 
expression may provide an alternative route to amphotericin-B resistance. We speculate 485 
that reduced flippase activity may lead to changes in membrane ergosterol content or 486 
accessibility, thereby reducing the efficiency of amphotericin-B binding and uptake. 487 
Therefore, functional characterisation of the syntenic Leishmania orthologues of the T. 488 
brucei flippases may provide additional insights into the processes that drive the anti-489 
leishmanial action of amphotericin-B.  490 
In summary, using our genome-scale BSF T. brucei RNAi library we have identified 491 
a panel of putative anti-leishmanial drug efficacy determinants, highlighting two candidate 492 
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cross-efficacy determinants, as well as roles for multiple flippases in the action of 493 
amphotericin-B. The findings from this orthology-based chemogenomic profiling approach 494 
substantially advance our understanding of anti-leishmanial drug mode-of-action and 495 
potential resistance mechanisms, and should facilitate the development of improved 496 
therapies, as well as surveillance strategies to identify drug-resistant parasites.  497 
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Methods 498 
T. brucei strains 499 
MITat1.2/2T1 BSF T. brucei (75) were maintained in HMI9 (50) (Invitrogen, 500 
LifeTech) supplemented with 10% foetal calf serum (Sigma) at 37°C/5% CO2. Transfection 501 
was carried out in either cytomix or Tb-BSF buffer (76), for integration at the 2T1 ‘landing 502 
pad’ (75, 77) or Tb927.9.6360-80, respectively, using a Nucleofector (Lonza) set to 503 
programme X-001. Transformants were selected in 2.5 µg.ml-1 hygromycin, 2 µg.ml-1 504 
puromycin or 10 µg.ml-1 blasticidin, as appropriate. The BSF T. brucei RNAi library was 505 
maintained in 1 µg.ml-1 phleomycin and 5 µg.ml-1 blasticidin (34). For growth assays, 506 
cultured BSF T. brucei were seeded at ~105 cells.ml-1, counted using a haemocytometer, 507 
and diluted back every 24 hours, as necessary, for three days in the absence of 508 
antibiotics. All selective antibiotics were purchased from Invivogen. 509 
 510 
Drug sensitivity assays 511 
Half-maximal effective concentrations (EC50) of the anti-leishmanial and anti-512 
trypanosomal drugs (sodium stibogluconate, GSK; paromomycin, Sigma; miltefosine, 513 
Paladin; amphotericin-B, E R Squibb, UK; pentamidine, Sigma; suramin, TDR/WHO), and 514 
neomycin (G418, Invivogen) were determined over 78 or 30 hours. BSF T. brucei were 515 
seeded at 2x103 (or 2x105) cells.ml-1 in 96-well plates in a 2-fold dilution series of each 516 
drug; assays were carried out in the absence of other antibiotics. After 72 or 24 hours, 517 
resazurin (Sigma) in PBS was added to a final concentration of 12.5 µg.ml-1 per well, and 518 
the plates incubated for a further 6 hours at 37°C. Fluorescence was determined using a 519 
fluorescence plate reader (Molecular Devices) at an excitation wavelength of 530 nm, an 520 
emission wavelength of 585 nm and a filter cut-off of 570 nm (78). Data were processed in 521 
Microsoft Excel, and non-linear regression analysis carried out in GraphPad Prism. The 522 
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short-term kinetics of killing in high concentration drug (>EC99) were determined in 523 
triplicate over 24 hours from a starting cell density of 1x105 cells.ml-1. 524 
 525 
T. brucei RNAi library screening and RIT-seq 526 
RNA library screening was carried out as previously described (34). Briefly, library 527 
expression was induced in 1 µg.ml-1 tetracycline (Sigma) for 24 hours prior to selection in 528 
each anti-leishmanial drug at 1-3X EC50. Cell density was assessed daily using a 529 
haemocytometer and diluted to no less than 20 million cells in 100 ml media; induction and 530 
anti-leishmanial drug selection were maintained throughout. Once robust growth had been 531 
achieved for at least two days, genomic DNA was prepared for RNAi target identification. 532 
The RNAi cassettes remaining in the anti-leishmanial-selected RNAi libraries were 533 
amplified from genomic DNA using the LIB2F/LIB2R primers and sequenced on an 534 
Illumina HiSeq platform at the Beijing Genome Institute. 535 
The sequenced RNAi target fragments were mapped against the T. brucei strain 536 
TREU927 reference genome (release 6.0), as described (34). Briefly, mapping was carried 537 
out using Bowtie2 (79) set to ‘very sensitive local’ alignment and output SAM files were 538 
processed using SAMtools (80). The resultant BAM files were viewed against the 539 
reference genome in the Artemis genome browser (81). Reads containing the RNAi 540 
construct-specific 14-base barcode were identified using a custom script (34), and 541 
corresponded to at least 22% of reads from each selected RNAi library. This subset of 542 
reads were mapped against the TREU927 reference genome, as above. Plots were 543 
generated using the Artemis graph tool and processed in Adobe Photoshop Elements 8.0. 544 
Stacks of reads that included the 14-base barcode on the positive strand were used to 545 
define RNAi target fragment junctions and to assign high-confidence hits as those 546 
identified by at least two RNAi target fragments.  RNAi target fragment read numbers were 547 
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converted to RPKM (reads/kilobase/million reads mapped) to account for inter-library read-548 
depth variations when comparing RNAi library sequencing outputs. 549 
Alignments were carried out in Clustal Omega 550 
(https://www.ebi.ac.uk/Tools/msa/clustalo/), unrooted neighbour joining trees were 551 
formatted in Dendroscope 3 (http://dendroscope.org/) (82) and putative trans-membrane 552 
domains identified using TOPCONS (http://topcons.cbr.su.se/) (83). GO-term profiles were 553 
constructed using the GO analysis tool at http://tritrypdb.org. 554 
 555 
Plasmid and T. brucei strain construction and analysis 556 
Tb927.9.6360-80 locus deletion constructs were assembled incorporating targeting 557 
fragments flanking either a puromycin acetyltransferase (PAC) or a blasticidin-S 558 
deaminase (BSD) open reading frame. Deletion constructs were linearised with NotI/ApaI 559 
(NEB) to expose the flanking targeting fragments prior to transfection. Stem-loop RNAi 560 
constructs targeting Tb927.11.6680 (AAT15), Tb927.11.13000, Tb927.11.3350, 561 
Tb927.5.3560 (TbVAMP7B) and Tb927.5.3570 were assembled in pRPa-iSL (77). RNAi 562 
targeting fragments were designed using the RNAit primer design algorithm to minimise 563 
off-target effects (84). pRPa-iSL constructs were linearised with AscI (NEB) prior to 564 
transfection and targeted integration at the rDNA spacer ‘landing pad’ locus in 2T1 BSF T. 565 
brucei (75). Details of all primers are available upon request. Tb927.9.6360-80 allelic 566 
replacement was confirmed by Southern hybridisation following XhoI (New England 567 
Biolabs) digestion of genomic DNA. RNAi knockdown was confirmed by northern 568 
hybridisation of total RNA or, in the case of Tb927.11.6680, by RT-qPCR, as described 569 
(85). For Southern and northern hybridisation, digoxigenin-dUTP (Roche) labelled DNA 570 
probes were generated by PCR, hybridised and detected according to standard protocols 571 
and the manufacturer’s instructions. 572 
 573 
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Data availability 574 
Sequence data are available as FASTQ files at the European Nucleotide Archive 575 
(https://www.ebi.ac.uk/ena) under study accession number, PRJEB31973 (amphotericin-B, 576 
ERS3348616; miltefosine, ERS3348617; paromomycin, ERS3348618; sodium 577 
stibogluconate, ERS3348619).  578 
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Figure legends 856 
 857 
Figure 1 858 
Anti-leishmanial drug selection of a genome-scale T. brucei RNAi library. A) 859 
Representative EC50 charts showing the susceptibility of T. brucei to the anti-leishmanial 860 
drugs. Individual EC50 assays were carried out in quadruplicate; error bars represent 861 
standard deviation. Insets: structures of the anti-leishmanial drugs (downloaded from 862 
en.wikipedia.org/wiki/Sodium_stibogluconate and www.sigmaaldrich.com). B) Schematic 863 
showing bloodstream-form T. brucei RNAi library selection and RNAi fragment 864 
identification by RIT-seq. C) Growth during anti-leishmanial drug selection of the BSF T. 865 
brucei RNAi library; selection was initiated in 1.5X EC50, except for miltefosine (1.0X EC50), 866 
and adjusted as indicated (black arrows); induction in 1 µg.ml-1 tetracycline was 867 
maintained throughout. Genomic DNA prepared at the indicated times (red arrows). Insets: 868 
RNAi library-specific PCR.  869 
 870 
Figure 2 871 
Genome-scale maps showing hits in each screen. Illumina sequencing of the amplified 872 
RNAi target fragments identifies T. brucei orthologues of known Leishmania drug 873 
transporters and novel putative drug efficacy determinants. RNAi fragments amplified from 874 
each selective screen were mapped against the TREU927 T. brucei reference genome. 875 
Red bars correspond to T. brucei orthologues of known Leishmania drug transporters: 876 
AQP2-3, aquaglyceroporin-2-3 locus, Tb927.10.14160-70; MT, miltefosine transporter 877 
orthologue, Tb927.11.3350. The y-axes are truncated to 104 reads/kilobase/transcript. 878 
SSG, sodium stibogluconate; Pmm, paromomycin; Milt, miltefosine; AmB, amphotericin-B.  879 
 880 
Figure 3 881 
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TbAQP3, a T. brucei orthologue of Leishmania AQP1, is selective for sodium 882 
stibogluconate. A) Total (red) and RNAi construct-specific 14mer-containing (blue) reads 883 
mapping to the TbAQP2-3 locus, Tb927.10.14160-70. Targeted open reading frames 884 
highlighted in green; flanking open reading frames coloured grey. B) Sodium 885 
stibogluconate EC50 assay following deletion of the T. brucei AQP2-3 locus (aqp2-3). C) 886 
Sodium stibogluconate and D) pentamidine EC50 assays following expression of 
GFPAQP2 887 
(left panels) and GFPAQP3 (right panels) in aqp2-3 null T. brucei. Individual EC50 assays 888 
were carried out in quadruplicate. Error bars represent standard deviation. WT, T. brucei 889 
wild type for the AQP2-3 locus. 890 
 891 
Figure 4 892 
The T. brucei lysosomal major facilitator superfamily protein influences the efficacy 893 
of aminoglycoside drugs. A) Total (red) and RNAi construct-specific 14mer-containing 894 
(blue) reads mapping to the MFST locus, Tb927.9.6360-80. Targeted open reading frames 895 
highlighted in green; flanking open reading frames coloured grey. B) Unrooted neighbour 896 
joining tree comparing representative Leishmania MFST proteins with Tb927.9.6360-80 897 
(highlighted in green; see Fig. S3 for extended tree). C) Predicted trans-membrane 898 
organisation of the Tb927.9.6360-80 proteins and the selected Leishmania proteins (TM 899 
domains, vertical bars). D) MFST locus deletion strategy and Southern hybridisation 900 
confirming generation of heterozygous (-/+) and homozygous (-/-) MFST locus null T. 901 
brucei. X, XhoI; D, deletion probe; F, flanking probe; PAC, puromycin acetyltransferase; 902 
BSD, blasticidin S-deaminase; WT, wild type. E) Growth of WT and MFST locus null (mfst) 903 
T. brucei in culture. F-H) Representative EC50 assays comparing the sensitivity of WT and 904 
mfst T. brucei to F) suramin, G) paromomycin and H) neomycin. Inset charts summarise 905 
EC50 data from three independent biological replicates. Individual growth (E) and EC50 (F-906 
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H) assays were carried out in triplicate and quadruplicate, respectively. Error bars 907 
represent standard deviation. P-values derived from Student’s t-test (** P<0.01). 908 
 909 
Figure 5 910 
Pairwise comparisons identify putative amphotericin-B/miltefosine cross-efficacy 911 
loci. Pairwise comparisons of the sequenced outputs from the four selective screens. Data 912 
converted to reads per kilobase per million mapped reads (RPKM) to control for minor 913 
inter-library variations in read depth. Dashed lines represent stringent 100-read cut offs for 914 
each selected RNAi library converted to RPKM. High confidence cross-efficacy 915 
determinants highlighted in red in the top right quadrant following comparison of the 916 
miltefosine and amphotericin-B selected RNAi libraries. 917 
 918 
Figure 6 919 
T. brucei VAMP7B, Tb927.5.3560, and the action of amphotericin-B and miltefosine. 920 
A) Total (red) and RNAi construct-specific 14mer-containing (blue) reads mapping to 921 
Tb927.5.3550-70 following amphotericin-B and miltefosine selection. Targeted open 922 
reading frames highlighted in green; flanking open reading frames coloured grey. B) T. 923 
brucei population growth following TbVAMP7B (Tb927.5.3560) RNAi knockdown. Inset: 924 
confirmation of RNAi knockdown by northern blot following 24-hour induction in 1 µg.ml-1 925 
tetracycline; ethidium bromide stained gel shown as a loading control. C) Representative 926 
30-hour amphotericin-B EC50 assay following TbVAMP7B RNAi knockdown induced in 2 927 
ng.ml-1 tetracycline. Inset chart summarises Hill coefficient data for five biological 928 
replicates. D) The effect of TbVAMP7B RNAi knockdown on ECX for five biological 929 
replicates; data derived for each replicate from EC50 values and Hill coefficients presented 930 
in (C). E) Representative 30-hour miltefosine EC50 assay following TbVAMP7B RNAi 931 
knockdown induced in 2 ng.ml-1 tetracycline; data plotted to show population growth 932 
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relative to untreated T. brucei (uninduced or induced). Dashed ellipse highlights 933 
miltefosine-mediated complementation of the Tb927.5.3560 RNAi growth defect. F) Chart 934 
summarising T. brucei population growth in the presence or absence of TbVAMP7B RNAi 935 
in a subset of miltefosine concentrations from five independent biological replicates. 936 
Individual growth (B) and EC50 (C, E) assays were carried out in triplicate and 937 
quadruplicate, respectively. Error bars represent standard deviation. P-values derived from 938 
paired Student’s t-test (** <0.01; *** <0.001).  939 
 940 
Figure 7 941 
The T. brucei miltefosine transporter orthologue, Tb927.11.3350, influences 942 
miltefosine and amphotericin-B efficacy against T. brucei. A) Total (red) and RNAi 943 
construct-specific 14mer-containing (blue) reads mapping to Tb927.11.3350 following 944 
amphotericin-B (AmB) or miltefosine selection. Targeted open reading frames highlighted 945 
in green; flanking open reading frames coloured grey. B) T. brucei population growth 946 
following RNAi knockdown of Tb927.11.3350. Inset: confirmation of RNAi knockdown by 947 
northern blot; ethidium bromide stained gel shown as a loading control. C, D) 948 
Representative amphotericin-B and miltefosine EC50 assays following RNAi knockdown of 949 
Tb927.11.3350. Inset charts summarise data from three independent biological replicates. 950 
Individual growth (B) and EC50 (C, D) assays were carried out in triplicate and 951 
quadruplicate, respectively. Error bars represent standard deviation. P-values derived from 952 
Student’s t-test (* <0.05; ** <0.01). RNAi inductions were carried out in 1 µg.ml-1 953 
tetracycline. 954 
 955 
Figure 8 956 
Flippases influence the action of amphotericin-B. A) Neighbour joining phylogenetic 957 
tree showing the T. brucei and L. major flippases versus the S. cerevisiae flippases 958 
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(Neo1p, P40527; Drs2p, P39524; and DNF1-3, P32660, Q12675, Q12674) and a 959 
representative cation-transporting P-type ATPase (Pay2, E9P982). Schematics of 960 
predicted T. brucei and L. major flippases, including the miltefosine transporter (MT, red), 961 
and representative S. cerevisiae flippases (Neo1p and DNF3, blue) and P-type ATPase 962 
(Pay2, orange). Conserved domains (actuator: TGES [green triangle], DEGT [pink 963 
triangle]; and, phosphorylation, DKTGT [yellow triangle]), predicted signal peptides 964 
(vertical red bar) and predicted trans-membrane domains (vertical black bars) are 965 
highlighted. B) Total (red) and RNAi construct-specific 14mer-containing (blue) reads 966 
mapping to Tb927.11.13000 and Tb927.6.3550 following amphotericin-B selection. 967 
Targeted open reading frames highlighted in green; flanking open reading frames coloured 968 
grey. C) T. brucei population growth following RNAi knockdown of Tb927.11.13000. Inset: 969 
confirmation of RNAi knockdown by northern blot; ethidium bromide stained gel shown as 970 
a loading control.  D, E) Representative amphotericin-B and miltefosine EC50 assays 971 
following RNAi knockdown of Tb927.11.13000. Inset charts summarise data from three 972 
independent biological replicates. Individual growth (C) and EC50 (D, E) assays were 973 
carried out in triplicate and quadruplicate, respectively. Error bars represent standard 974 
deviation. P-values derived from Student’s t-test (* <0.05; ** <0.01). RNAi inductions were 975 
carried out in 1 µg.ml-1 tetracycline, unless otherwise stated. 976 
 977 
Figure 9 978 
Known and candidate drivers of anti-leishmanial drug efficacy in Leishmania. The 979 
key T. brucei proteins identified in our anti-leishmanial loss-of-function screen (left hand 980 
panel) and their Leishmania orthologues (right hand panel) represent candidate anti-981 
leishmanial drug efficacy determinants. Red denotes known Leishmania drivers of anti-982 
leishmanial efficacy whose loss-of-function reduces drug efficacy (see text for details). The 983 
strain prefix for the truncated gene IDs is at the top of each panel, with the exception of the 984 
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sterol biosynthetic enzymes recently shown to contribute to amphotericin-B efficacy 985 
against L. mexicana (73). Grey-filled circles (endosomes) and ellipses (lysosome) 986 
represent the endocytic system. The purple block represents membrane modified by 987 
changes in sterol biosynthesis and the putative action of the flippases and their β-subunit; 988 
changes in membrane composition anywhere in the endocytic system may influence the 989 
intracellular transit of amphotericin-B or its ability to form ion permeable channels. 990 
Tb927.11.3350 has an intracellular localisation in procyclic stage T. brucei; however, in the 991 
current absence of data from BSF T. brucei, we speculate that this protein localises to the 992 
plasma membrane in BSF T. brucei, as per its Leishmania orthologue. 993 
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